Performance Highlights | Sinwi Medical-B (6609.HK): Profit turning point is approaching, overseas layout is gradually showing results.
On September 2nd, China's neurointerventional medical device pioneer, Xinwei Medical (6609.HK), which is listed in Hong Kong, held its 2024 interim performance conference and provided detailed explanations of the company's performance in the first half of this year. The key points of Xinwei Medical's 2024 interim performance are as follows: steady revenue growth, approaching the breakeven point. From the core financial indicators, in the first half of the year, the company achieved revenue of 0.128 billion yuan, a year-on-year growth of 17.24%, demonstrating a steady growth trend and reflecting its strong market adaptability and business resilience in the face of complex and volatile financial market conditions and multiple challenges such as centralized procurement policies, which lay the foundation for the company's future development.
Xinwei Medical-B (06609) releases mid-term performance: gross profit of 82.281 million yuan, an increase of 3.22% year-on-year.
Xinwei Medical -B (06609) released the interim performance for the six months ending on June 30, 2024, the group...
Express News | Shanghai HeartCare Medical Technology H1 Gross Margin 64%
Express News | Shanghai HeartCare Medical Technology H1 Gross Profit RMB 82.3 Million
Express News | Shanghai HeartCare Medical Technology H1 Capex RMB 1.4 Million
Express News | Shanghai HeartCare Medical Technology H1 Revenue RMB 128.5 Million
HEARTCARE-B: ANNOUNCEMENT OF INTERIM RESULTS FORTHE SIX MONTHS ENDED JUNE 30, 2024
Xinwei Medical -B (06609.HK) will hold a board of directors meeting on August 30 to approve interim performance.
On August 20th, Gelonhui announced that Heartway Medical-B (06609.HK) will hold a board of directors meeting on August 30th, 2024 to approve the mid-term performance of the company and its subsidiary companies until June 30th, 2024, and consider the distribution of mid-term dividends (if any).
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Hong Kong stock concept tracking | The Ministry of Industry and Information Technology has issued a document! Regarding the brain-computer interface, institutions: Focus on the possibility of implementing scenarios (with concept stocks attached)
Tianfeng Securities believes that the brain-computer interface market has broad potential, frequent encouragement policies, and diverse application scenarios.
Hong Kong Stock Concept Tracking | New Advances in Brain-Computer Interface Technology! Neuralink begins recruiting a second patient (with concept stock)
Musk announced that after 100 days of successful surgery for the first patient involved in the brain-computer device implantation experiment at the beginning of the year, Neuralink (Neuralink) has officially begun recruiting a second patient to receive a brain-computer implantation.
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
HEARTCARE-B: ANNUAL REPORT 2023
Interpretation of Xinwei Medical-B (6609.HK) Annual Report: Innovation and Globalization, Therapeutic Products Save Development Potential
The concept of “new quality productivity” was emphasized many times during the two sessions. In particular, the medical device industry, the high-end medical device sector, which is driven by scientific and technological innovation as the core driving force, is undoubtedly also moving towards a rapid development path as an important indicator for measuring the country's level of high-tech development.
Xinwei Medical-B (06609.HK) announced annual results: business focus on driving product structure transformation, gross margin rose to 70.5%, losses narrowed, and major neurointerventional treatment devices are about to be launched
Gelonghui March 28 | Xinwei Medical-B (06609.HK) announced its annual results. For the year ended December 31, 2023, the company's revenue increased to RMB 232.3 million, an increase of 26.9% year on year, and loss before tax narrowed to RMB 102.9 million, a year-on-year decrease of 48.9%. With the expansion of business scale and the effects of cost control and efficiency measures, the company's gross margin increased 2.6 percentage points to 70.5%, and the share of sales and distribution expenses and administrative expenses decreased to 66.2% (2022:91.8%). In 2023, in order to adapt to a rapidly changing city
Xinwei Medical-B (06609) announced 2023 annual results with revenue of 232 million yuan, an increase of 26.9% year-on-year
Xinwei Medical-B (06609) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 232 million yuan (RMB, same below) during the period, an increase of 26.9%; the parent company's owners should have accounted for a loss of 94.012 million yuan, a year-on-year decrease of 53.08%; and a basic loss of 2.47 yuan per share.
HEARTCARE-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2023
Xinwei Medical-B (06609.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 18, 丨 Xinwei Medical-B (06609.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and handle any other business.
Home to Linjiang: Brain-computer interface is a trend where Hong Kong stocks are not approved
As an emerging industry, brain-computer interface technology is mainly divided into hardware layer and software layer.
No Data
No Data